A Cancer Curing Drug Molecule that is made in India !!

Cancer Cure Programme

In a first, 24 researchers from several labs have designed and synthesised 'Disarb', a drug which induces the death of cancer cell, and carried out preliminary tests as well, It has been patented, a first for a home-growth drug , developed for targeted therapy of cancer.

cancer biologist, chemists, clinicians,and specialist in bioinformatics belonging to different labs,will soon pool their expertise for a multi-crore rupee project aptly titled "Glue Grant" to carry out pre-clinical

tests of the drug Disarib which bring about the death of cancer cells .

The Department of Biotechnology (DBT)

New Delhi has approved this collaborative effort to produce the first home grown drug,which has been found to be better than the one ( Codenamed ABT199) approved by the Food and Drug Administration (FDA) of the united State for it does not set off any side effects.

Designed and Synthesised by research from eight different research groups spread over labs in Mumbai, Thiruvananthuapurum, Benguluru, and with contribution from a couple of Indian scientist at the Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Disarib belongs to the class of "designer molecules" that zero in on rogue cells as part of the targeted therapy method to combat cancer. To start with, the efficiency will be checked out on cancer cell of patient suffering from leukaemia and lymphoma. Besides Disarib new drug with similar to action against cancer cell will be tested for toxicity and efficacy as part of the new project says prof.Sathees Raghvan of the Department of Biochemistry, Indian Institute of scirnce, Benguluru.

The result have been published in Biochemical Pharmacology .

Following a number of preliminary tests and analyses, the drug was tested in cancer cell lines , animal models, patient samples and more. the team even utilised a humalised model of tumour in mice for ovarian carcinoma in addition three independent mouse tumour models for investigating the tumour regression property of disarib the molecule was found effective against a range of cancer leukaemia, lymphoma, breast cancer , ovarian cancer and colon cancer .

"In all cases , our molecules performed better than ABT199 which is why we decide to patent this molecule " said Prof.Raghavan.

Pharmaceuticals companies have shown some case interest, which is very encouraging says Prof. Raghavan though he caution the results of study approved by the DBT will decide when the drugs will be available in the market.